Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $156.03M |
| Gross Profit (TTM) | $-252.63M |
| EBITDA | $-355.78M |
| Operating Margin | -25827.00% |
| Return on Equity | -8.18% |
| Return on Assets | -17.00% |
| Revenue/Share (TTM) | $1.51 |
| Book Value | $10.69 |
| Price-to-Book | 2.36 |
| Price-to-Sales (TTM) | 16.07 |
| EV/Revenue | 10.32 |
| EV/EBITDA | -7.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -94.20% |
| Shares Outstanding | $103.29M |
| Float | $88.24M |
| % Insiders | 1.37% |
| % Institutions | 107.81% |
Volatility is currently contracting
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM).
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM).
LOS ANGELES--(BUSINESS WIRE)---- $BEAM--BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law.
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. (“Beam” or the “Company”) (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM).
Beam Therapeutics Inc. (BEAM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript
BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months Follow-Up, Data Show Long-Term Durability of In Vivo Correction of Disease-causing Mutation with Single Dose of BEAM-302 Treatment with BEAM-302 Increased Total and Functional AAT and Decreased Neutrophil Elastase Activity in Circulation BEAM-302 Led to Reduction in Circulating Mutant Z-AAT and Corresponding Decrease in Toxic Circulating Z-polymers Safety Profile of BEAM-302 Remains Consistent with LNP-based Therapies Dosing Underway in Global Pivotal Cohort Designed to Support Potential U.S. Accelerated Approval Beam to Host Investor Webcast Today, September 8, 2026, at 7:00 a.m. ET CAMBRIDGE, Mass.
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Eric Foster as chief commercial officer. Mr. Foster will lead Beam's commercial organization and strategy as the company advances multiple product candidates across its hematology and genetic disease franchises toward potential launches.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BEAM and any ticker you trade — then tracks every position and per-strategy win rate.
